Clofazimine broadly inhibits coronaviruses including SARS-CoV-2 - Yuan, Shuofeng; Yin, Xin; Meng, Xiangzhi; Chan, Jasper Fuk-Woo; Ye, Zi-Wei; Riva, Laura; Pache, Lars; Chan, Chris Chun-Yiu; Lai, Pok-Man; Chan, Chris Chung-Sing; Poon, Vincent Kwok-Man; Lee, Andrew Chak-Yiu; et al. (Nature (London), 2021)
Keywords: 13; 13/1; 13/21; 38/39; 631/250/255/2514; 631/326/596/1296; 631/326/596/4130; 64; Adenosine Monophosphate - analogs & derivatives; Adenosine Monophosphate - pharmacology; Adenosine Monophosphate - therapeutic use; Alanine - analogs & derivatives; Alanine - pharmacology; Alanine - therapeutic use; Animals; Anti-Inflammatory Agents - pharmacokinetics; Anti-Inflammatory Agents - pharmacology; Anti-Inflammatory Agents - therapeutic use; Antiviral Agents - pharmacokinetics; Antiviral Agents - pharmacology; Antiviral Agents - therapeutic use; Antiviral drugs; Bioavailability; Biological Availability; Cell Fusion; Cell Line; Clofazimine; Clofazimine - pharmacokinetics; Clofazimine - pharmacology; Clofazimine - therapeutic use; Coronaviridae; Coronavirus - classification; Coronavirus - drug effects; Coronavirus - growth & development; Coronavirus - pathogenicity; Coronaviruses; COVID-19; Cricetinae; DNA helicase; DNA Helicases - antagonists & inhibitors; Dosage and administration; Drug Synergism; Female; Glycoproteins; Health services; Humanities and Social Sciences; Humans; Inflammation; Leprosy; Life Cycle Stages - drug effects; Male; Mesocricetus; Middle East respiratory syndrome; Mortality; multidisciplinary; Pandemics; Pathogenesis; Pre-Exposure Prophylaxis; Respiratory diseases; Respiratory tract; SARS-CoV-2 - drug effects; SARS-CoV-2 - growth & development; Science; Science (multidisciplinary); Severe acute respiratory syndrome coronavirus 2; Species Specificity; Spike glycoprotein; Spike Glycoprotein, Coronavirus - antagonists & inhibitors; Transcription, Genetic - drug effects; Transcription, Genetic - genetics; Viral diseases; Zoonoses; China; United States--US